Elysium Health, the New York-based longevity company best known for its NAD+-boosting supplement Basis, has announced its move into peptides.
It said it plans to offer six additional peptides through its Elysium Health Rx service and has launched two research initiatives.
The announcement follows an interim enforcement-discretion policy from the US Department of Health and Human Services (HHS).
Under the policy, HHS does not intend to take enforcement action against 503A compounding pharmacies, federal facilities or licensed physicians that compound with six peptide bulk substances (BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500), provided detailed safeguards are met.
This does not make the peptides FDA-approved or add them to the 503A bulks list and HHS can revisit the decision if safety signals or quality concerns emerge.
Elysium said the six peptides are expected to be available through Elysium Health Rx by the end of the year, subject to evaluation by independent board-certified physicians.
The company also stressed that human clinical evidence for the peptides is limited.
Alongside the access plans, Elysium has launched the Peptide Evidence and Evaluation Resource (PEER), which will supply high-purity, characterised peptides to universities, hospitals, nonprofits and other qualified institutions through a traceable supply chain.
It also plans TIME-PEP, a study run through its Aging Research Center that will examine epigenetic changes linked to peptide use and their potential relationship to biological age.
Co-founder and CEO Eric Marcotulli said unregulated suppliers and research-use-only products pose “a genuine public health challenge” and argued for higher standards in the legitimate market.
A divisive policy
The policy has split opinion. HHS framed it as a way to steer consumers away from research-use-only peptides supplied by foreign manufacturers and compounding groups welcomed it.
Critics argue the peptides have not yet been shown to be safe.
FDA staff recommended against listing any of the seven peptides ahead of July’s Pharmacy Compounding Advisory Committee meeting, citing weak characterisation and limited safety and efficacy data.
The committee nonetheless backed the six and some groups have since asked HHS to hold the policy.
What it means for nutraceuticals
The announcement comes as consumer interest in peptides surges.
Google searches for the term have risen by roughly 200% in the past 12 months, according to Google Trends data.
Supplement brands have already capitalised on that appetite with established ingredients such as collagen peptides and bioactive peptides derived from food proteins — Elysium itself sells a collagen system that pairs collagen peptides with nicotinamide riboside.
The six peptides covered by the HHS policy are a different proposition. Regulators have treated BPC-157 as an unapproved drug that cannot legally be sold as a dietary supplement and testing body BSCG says the same of TB-500.
The HHS policy doesn’t change that, since compounding under enforcement discretion is not FDA approval.
Elysium will offer the peptides through independent physicians rather than as supplements, but it is a notable move for a company that built its name on the supplement side of the line.
That is why categorisation matters. “Peptide” describes a chemical structure and being a peptide confers neither FDA approval nor lawful supplement status.
The Council for Responsible Nutrition, the US supplement trade association, describes lawful supplements and grey-market peptides as “worlds apart."
As supplement brands move beyond established peptide ingredients towards drug-like compounds, blurring that distinction risks damaging consumer trust in the category.
For formulators and brand owners, the lesson is that clinical evidence, ingredient characterisation and transparent manufacturing will likely determine who benefits as consumer interest in peptides continues to grow.
